TR Pharm has entered into a colloboration with Toyama Chemical to license and market Iguratimod for the treatment of rheumatoid arthiritis in Turkey and MENA region.
The product, originally discovered by Toyama Chemical, is a novel disease modifying anti-rheumatic drug (DMARD) jointly developed in Japan by Eisai and Toyama Chemical based on a co-development and license agreement previously concluded between the two companies.
By providing the product as a new option for the pharmacological treatment of rheumatoid arthritis in Turkey, TR Pharm and Toyoma Chemical believe that further contributions to address the diversified needs and improve the quality of life of rheumatoid arthritis patients will be adressed.
Iguratimod was approved in Japan in June 2012, and was subsequently launched the following September for the treatment of Rheumatoid arthritis
About Toyama Chemical Co., Ltd.
Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan, is a leading pharmaceutical company in Japan, working to meet the worldwide demand for effective drugs to overcome new and intractable diseases. Toyama has concentrated its R&D in three fields:Infectious Field, Neurological Diseases Therapeutic Field, and Inflammatory Field. Its core strength is in the development of new pharmaceuticals which is evidenced by Toyama’s numerous technology exports and royalty income, which is the highest among mid-sized Japanese pharmaceutical companies.
Pharmaceuticals now in the pipeline include T-705, an antiviral agent; and T-817MA, a treatment for Alzheimer’s disease. Toyama continues to form strategic partnerships with domestic and overseas pharmaceutical manufacturers to deliver products quickly and efficiently to medical institutions around the world.
About TR Pharm
TR Pharm is a pharma start-up focused on innovation with investments into R&D and a cutting edge biotechnological manufacturing capability with the aim of becoming a regional commercial player based out of Turkey.
TR Pharm focuses on the launch of new and innovative medicines starting from registration and accomplishment of clinical programs in all phases, as well as building a biotech manufacturing facility in Turkey for the supply of monoclonal antibodies to CIS and MENA region besides the local market. TR Pharm has a wide product portfolio, led by oncology, virology, inflammatory and rare diseases.